Ultragenyx Pharmaceutical RARE announced that the FDA has granted the Breakthrough Therapy designation to its investigational ...

The FDA has granted Breakthrough Therapy designation to setrusumab to reduce fracture risk with osteogenesis imperfecta type I, III, or IV.

After five years of research, CDRI discovers a promising protein-drug combo targeting osteoporosis induced by chronic kidney ...

A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small ...

He points to the mAb CDP-7851 (also known as AMG-785; developed by Amgen/UCB) — which targets sclerostin, a protein that inhibits bone formation — as an exciting potential product.

Ahmedabad: Zydus Lifesciences Ltd, Ahmedabad has signed a collaborative research agreement with Central Drug Research ...

Romosozumab attaches itself to a natural substance in the body called sclerostin, which regulates the formation and breakdown of bone. It is the first new osteoporosis treatment in a decade.

Osteoporosis is a common bone disease characterized by the progressive loss of bone mass and bone density. Osteoporosis ...

NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RARE), a biopharmaceutical company focused on the development of ...

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its ...

Evenity is the first sclerostin inhibitor to be approved for osteoporosis, and is thought to work largely by encouraging the formation of new bone, with a lesser inhibitory effect on bone destruction.